Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Nanoparticle-based flow virometry for the analysis of individual virions
Anush Arakelyan, Wendy Fitzgerald, Leonid Margolis, Jean-Charles Grivel
Anush Arakelyan, Wendy Fitzgerald, Leonid Margolis, Jean-Charles Grivel
View: Text | PDF
Technical Advance AIDS/HIV

Nanoparticle-based flow virometry for the analysis of individual virions

  • Text
  • PDF
Abstract

While flow cytometry has been used to analyze the antigenic composition of individual cells, the antigenic makeup of viral particles is still characterized predominantly in bulk. Here, we describe a technology, “flow virometry,” that can be used for antigen detection on individual virions. The technology is based on binding magnetic nanoparticles to virions, staining the virions with monoclonal antibodies, separating the formed complexes with magnetic columns, and characterizing them with flow cytometers. We used this technology to study the distribution of two antigens (HLA-DR and LFA-1) that HIV-1 acquires from infected cells among individual HIV-1 virions. Flow virometry revealed that the antigenic makeup of virions from a single preparation is heterogeneous. This heterogeneity could not be detected with bulk analysis of viruses. Moreover, in two preparations of the same HIV-1 produced by different cells, the distribution of antigens among virions was different. In contrast, HIV-1 of two different HIV-1 genotypes replicating in the same cells became somewhat antigenically similar. This nanotechnology allows the study of virions in bodily fluids without virus propagation and in principle is not restricted to the analysis of HIV, but can be applied to the analysis of the individual surface antigenic makeup of any virus.

Authors

Anush Arakelyan, Wendy Fitzgerald, Leonid Margolis, Jean-Charles Grivel

×

Figure 7

Detection of HIV-1 virions in blood plasma and analysis of their antigenic makeup.

Options: View larger image (or click on image) Download as PowerPoint
Detection of HIV-1 virions in blood plasma and analysis of their antigen...
Normal blood plasma (A) with HIV-1SF162 suspended at a concentration similar to that found in the infected donors (104–105 copies per milliliter) and (B) plasma from an HIV-1–infected donor. Because of the low concentration, virus was first concentrated from 40-ml samples by capturing it on fluorescence-labeled VRC01-MNPs followed by separation on magnetic columns. Then, captured virions were stained with anti–gp120 2G12 antibodies and once again separated from free antibodies on magnetic columns. Note that as a result of the concentration procedure, these preparations contain substantially more MNPs than those analyzed in Figure 2. (A) VRC01-MNPs suspended in control virus-free plasma and incubated with anti-gp120 antibodies (left panel); MNP-captured HIV-1 from virus-spiked normal plasma incubated with anti–gp120 isotype control antibody (center panel) or with anti–gp120 2G12 antibodies (right panel). (B) HIV-1 captured from the plasma of an infected individual with VRC01-MNPs was incubated with either gp120 isotype control (left panel) or visualized with anti–gp120 2G12 antibodies (right panel). (C and D) HIV-1 captured from the plasma of an infected individual was stained for HLA-DR (C) or LFA-1 (D). Left panels: isotype controls. Right panels: specific staining of HIV-1 captured by VRC01-MNPs with anti–HLA-DR (C) and anti–LFA-1 (D) antibodies. On each plot, the fraction of events in their respective gates is expressed as a percentage of the total events in the plot.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts